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RU-486; Safe? Effective? Banned! Why
Would the Food and Drug Administration
Ban a Drug With Such Potential?*
I. Introduction
In 1973, the U.S. Supreme Court ruled that a woman has a
fundamental right to terminate an unwanted pregnancy through
abortion.' Although individual states may regulate this right,2 to
date, a woman may still legally obtain an abortion in the United
States.
Leona Benten a is a twenty-nine year old resident of California,"
who was faced with the difficult decision of whether or not to termi-
nate her pregnancy. Ms. Benten underwent a surgical abortion under
general anaesthesia in the mid-1980's and was weary of enduring the
procedure a second time.
On July 1, 1992, customs officials met Ms. Benten at John F.
Kennedy International Airport as she returned from London, Eng-
land.5 Ms. Benten was found to be carrying one dose of-the drug
Mifepristone,6 commonly know as RU-486, which she had intended
to use to end her unwanted pregnancy. RU-486 was banned by the
Food and Drug Administration (FDA) from United States importa-
tion due to its health risks and, therefore, was seized from Ms.
Benten's luggage by customs officials.
The United States Food and Drug Administration primarily
seeks to ensure that new drugs are safe and effective for their pro-
posed use in order to protect the general public's welfare. The Fed-
eral Food, Drug and Cosmetic Act (FDCA)7 requires that drugs be
* Several new developments have arisen regarding RU-486 between the time this
Comment was originally written and the time it went into print. A note at the end of the
comment highlights recent developments, will summarize the developments to date.
1. See Roe v. Wade, 410 U.S. 113 (1973).
2. See Planned Parenthood v. Casey, 112 S. Ct. 2791 (1992).
3. Leona Benten at the time, was in her seventh week of an unwanted pregnancy. After
consulting with her gynecologist, Louise Tyrer, Ms. Benten was informed that she could termi-
nate her pregnancy by medical means not involving surgery. After explaining the procedure,
risks and side effects, Dr. Tyrer wrote Ms. Benten a prescription for one dose of RU 486 to
end her pregnancy. Ms. Benten then traveled to London, where she had the prescription filled.
See Benten v. Kessler, 799 F. Supp. 281 (E.D.N.Y. 1992).
4. Benten v. Kessler, 799 F. Supp. at 283.
5. See Philip J. Hilts, Abortion Pills Are Confiscated By U.S. Agents, N.Y. TIMES, July
2, 1992, at A12.
6. Id.
7. Federal Food, Drug and Cosmetic Act, Ch. 675, §§ 1-902, 52 Stat. 1040 (1938)
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proven safe and effective through scientific evidence before they are
approved for commercial marketing within the United States.' Rec-
ognizing the need which some individuals may have for immediate
drug treatment, 9 the FDA revised its Regulatory Procedures Manual
creating the "personal use exception" 10 for those who wish to obtain
drugs that have not yet been approved in the United States. This
exception allows for the importation of small doses of untested drugs
from abroad for personal use." Included within this exception are
drugs for all life-threatening or serious conditions, as well as drugs
for less serious medical problems where the product "is not known to
represent a significant health risk." 2
On July, 9, 1989, the FDA issued Import Alert 66-47 which
stated that RU-486 was subject to "automatic detention" and that
customs agents were to "automatically detain all shipments of unap-
proved abortifacient drugs" being imported into the United States."3
The Import Alert was issued because the FDA concluded that the
intended use of abortifacients could pose safety risks to the user.4
RU-486 has been approved for use in numerous countries,"6 but
has not yet been introduced in the United States.' 6 The political con-
troversy surrounding abortion in this country has stalled the intro-
duction and testing of RU-486. This Comment discusses in Section
II the drug RU-486, its health risks, and its possible uses; Section
III examines the FDA's approval system; Section IV discusses the
drug approval system of Great Britain; Section V compares the
United States system with that of Great Britain; Section VI dis-
cusses the drug approval systems of other countries; Section VII sets
forth the reasons why RU-486 has not yet been approved for use in
this country; and Section VIII discusses the recent history of RU-
486 in the United States including Leona Benten's unsuccessful at-
tempt to challenge the FDA's ban.
(current version at 21 U.S.C. §§ 301-392 (1982)).
8. See 21 U.S.C. § 355(d) (1982).
9. In recent years, people who are critically ill with cancer or Acquired Immune Defi-
ciency Syndrome (AIDS) are willing to try drugs that have not yet been approved in the
United States in an effort to extend their life expectancy.
10. See Benten v. Kessler, 799 F. Supp. 281, 285 (E.D.N.Y. 1992).
I1. Id.
12. Id. (quoting the Food and Drug Administration Regulatory Procedure Manual).
13. Id. at 286. See also, THE AMERICAN LAWYER, Sept. 1992, at 101.
14. See Benten v. Kessler, 799 F. Supp. at 286.
15. To date, RU-486 has been approved for use as an abortifacient in France, the
United Kingdom, Sweden and China.
16. See Steven Miles, Mifepristone is a Pill That the U.S. Should Learn to Swallow,
STAR TRIBUNE, Sept. 21, 1992, at 13A.
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II. Mifepristone (RU-486)
A. Background of RU-486
RU-486 is a revolutionary contraceptive/abortifacient which
gained notoriety in the late 1980's. The scientific and medical com-
munities have identified RU-486 as one of the most effective and
safe methods of terminating an abortion absent a surgical
procedure.1"
Dr. Etienne-Emile Baulieu first synthesized RU-486 in 1980
while he was associated with the French drug company Roussel
Uclaf."8 On September 27, 1989, Dr. Baulieu received the Albert
Lasker Medical Research Award for the research and development
associated with this new drug.' 9
B. How RU-486 Works
The body of a pregnant woman secretes progesterone to prepare
the uterus for the implantation and retention of a fertilized egg.20
RU-486 is "an antihormone, a synthetic chemical, that when taken
within the first seven weeks of pregnancy induces an abortion by
blocking the action of progesterone and prompting the uterus to shed
the egg."'" The entire procedure "involves the ingestion of 600 milli-
grams of Mifepristone on an empty stomach, followed forty-eight
hours later by the ingestion of Cytotec [or another prostaglandin]." 22
Prostaglandins cause contractions of the uterus, and are adminis-
tered sequentially with RU-486 to increase the drug's overall
effectiveness.23
C. Effectiveness of RU-486
The medical community viewed RU-486 as a medical break-
through, offering women a safe and effective manner of terminating
an unwanted pregnancy without having to undergo surgery. 2 Each
year approximately 1.6 million women in the United States undergo
elective abortions. 25 Surgical abortion is the most commonly used al-
17. See David Grimes, Perspective on the 'Abortion Pill', LA. TIMES, June 17, 1991, at
5.
18. Leonard A. Cole, Abortions Will Be Moot Soon, N.Y. TIMES, Oct. 9, 1989, at A17.
19. See Sylvia Rubin, Killer or Medical Hero; French Inventor Thinks Soon, S.F.
CHRON., Aug. 2, 1991, at B3.
20. Robin Herman, In France, - OUI!, In The U.S. - Not Yet; The Politics of the
Abortion Pill, WASH. POST, Oct. 3, 1989, at Z12.
21. See Fern Schumer Chapman, The Politics of the Abortion Pill, WASH. POST, Oct. 3,
1989, at Z13.
22. Benten v. Kessler, 799 F. Supp. 281, 284 (E.D.N.Y. 1992).
23. See Chapman, supra note 21, at Z13.
24. See Miles, supra note 16, at 13A; see also Grimes, supra note 17, at 5.
25. See Grimes, supra note 17, at 5.
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ternative method of terminating a pregnancy" and requires anaes-
thetization so that a woman's uterus may be dilated, scrubbed and
evacuated.2" Women who have terminated pregnancies through sur-
gical abortion and clinical trials of RU-486 reported that the abor-
tion with RU-486 was "two thousand times better" and "far less
violent" than the surgical alternative.28
Roussel Uclaf noted that RU-486 is eighty-five percent effective
when taken alone. 29  When taken in conjunction with a pros-
taglandin, the drug's effectiveness increases to ninety-six percent. 30
D. Safety of RU-486
RU-486 was approved for use in France in 1988.31 Since then,
over 110,000 women have safely used the contraceptive/abortifa-
cient. 32 The drug induces bleeding comparable to a menstrual period
for approximately one week, and a few patients feel slight nausea
and cramps. 33 The drug remains in the body for only forty-eight
hours, and the side effects are "short-lived. 34
E. Other Possible Uses for RU-486
Recently, RU-486 was found to be 100 percent effective when
used as a "morning-after" contraceptive.3 5 "The standard morning-
after pill, 31 a high dose version of the oral contraceptive, is given up
26. See Benten v, Kessler, 799 F. Supp. at 284.
27. The procedure for a surgical abortion are generally not recommended until the
eighth week of pregnancy and requires the uterus be dilated so that the vagina, vulva and
cervix can to be scrubbed. The cervix is then dilated to allow for the evacuation of the uterus.
To do so, a suction curette aspirator is inserted into the uterus to remove the placenta or fetal
parts. Any remaining parts of the placenta or fetus must then be removed with a sharp curet
to avoid continued bleeding and infection. See id. n.2 (citing ROSCOE N. GRAY, ATTORNEY'S
TEXTBOOK OF MEDICINE P 311.84(I) (3d ed. 1991)).
28. For a short period of time, RU-486 was being tested in California until Roussel
Uclaf ceased supplying the drug in the United States due to the hostile environment of the
abortion issue. See Miles, supra note 16, at 5.
29. See Herman, supra note 20, at Z12.
30. Id.
31. France Becomes First Western Nation to Approve Abortion Pill, L.A. TIMES, Sept.
24, 1988, Part 1 at 4.
32. See Hilts, supra note 5, at A12.
33. See Leonard A. Cole, The End of the Abortion Debate, 138 U. PA L. REV. 217, 219
(1989).
34. See Mindy J. Lees, Note, I Want a New Drug: RU-486 and the Right to Choose, 63
S. CAL. L. REV. 1113, 1118 (1990) (citing Fraser, A Passing Grade, MOTHER JONES, June
1988 at 33).
35. Glasgow researchers administered either RU-486 or the standard morning-after pill
to eight hundred women who sought emergency help after having unprotected intercourse or
contraceptive failure. Of the women who received RU-486, none became pregnant and fewer
suffered from nausea in comparison to the standard morning-after pill. Peter Pallot, Morning-
After Birth Pill Proves lOOpc Effective, THE DAILY TELEGRAPH, Oct. 9, 1992, at 7.
36. The most common morning-after pill used by doctors is Ovral. The usual dosage for
this emergency treatment to prevent pregnancy requires the administering of two pills taken as
soon after intercourse as possible followed by two additional pills 12 hours later. Dr. Howard
Seiden, 'Morning-after pill' RU 486 Should Not Be Blocked, THE GAZETTE (Montreal), Oct.
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to seventy-two hours after unprotected intercourse or after contra-
ceptive failure. ' 37 "Morning-after" birth control pills are adminis-
tered primarily in Planned Parenthood clinics, emergency rooms
treating sexually assaulted women, and college health clinics as pro-
tection from becoming pregnant. 8 RU-486, when used as a "morn-
ing-after" contraceptive, as opposed to an abortifacient, is believed
to prevent the implantation of a fertilized egg in the uterine wall.39
Other options for emergency postcoital or "morning-after" con-
traceptives are the insertion of a copper-type intrauterine device
(IUD) or the administering of the drug Danazol (Cyclomen)." ° The
drawbacks to these alternatives are the side effects of the IUD"', and
the failure rate of Danazol." RU-486 has also shown promise as a
treatment for brain tumors, endometriosis and depression as well as
breast, ovarian and prostate cancer.43 Experts noted that RU-486
may also be used to treat several other diseases including glaucoma,
adrenal cancer and Acquired Immune Deficiency Syndrome
(AIDS)." Dr. Steven Grunberg of the University of Southern Cali-
fornia stated that 200 patients are currently being chosen for a new
study using RU-486 as a treatment for benign brain tumors that can
cause seizures, blindness and paralysis. 5
III. The Food and Drug Administration
A. History and Development of the FDA
The FDA, established in 1927, was originally known as the
Food, Drug and Insecticide Administration."6 In 1931 the name was
changed to the Food and Drug Administration. 47
Before 1906, no governmental body regulated the sale of drugs
in the United States. Moreover, during the next thirty-two years, all
attempts to regulate drug sales were ineffective.4" Unfortunately, it
31, 1992, (Living Section), at 5.
37. Pallot, supra note 35, at 7.
38. Gina Kolata, New Use is Found For Abortion Pill, N.Y. TIMES, Oct. 8, 1992, at Al.
39. See Pallot, supra note 35, at 7.
40. See Dr. Howard Seiden, This Country Should Allow Women Access to RU 486,
TORONTO STAR, Oct. 29, 1992, (Life Section), at 3.
41. Insertion of the IUD can cause pain and bleeding and can on rare occasion cause
perforation of the uterus, pelvic infections which may result in permanent infertility as well as
heavier and more crampy periods. Id.
42. Reports on the failure rate of Danazol have been as high as 10 percent. Id.
43. Cancer Patient Can Get Unapproved Abortion Pill, N.Y. TIMES, July 30, 1992, at
A22.
44. RU-486 Will Be Tested On Brain Tumor Patients, CHICAGO TRIBUNE, Oct. 16,
1992, at 7.
45. Id.
46. See Beth E. Myers, The Food and Drug Administration's Experimental Drug Ap-
proval System: Is it Good for Your Health?, 28 Hous L. REV. 309, 311 (1991).
.;47. , Id., .;:
48. Id., see also Myron L. Marlin, Treatment INDs: A Faster Route to Drug Approval,
RU-486
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took a tragedy for Congress to pass the 1938 Food, Drug and Cos-
metic Act to regulate the sale of drugs.49 In 1938, more than one
hundred children died from ingesting a liquid sulfa drug called Elixir
of Sulfanilamide. Massengill Company, in formulating this liquid
sulfa drug, used "diethylene glycol" as a solvent without first testing
the chemical's safety. After distribution to the public, the drug later
proved extremely toxic.50
In that same year, Congress passed the Food, Drug and Cos-
metic Act, giving the FDA authority to regulate "all drugs and vac-
cines sold in interstate commerce."51 The act also required that drug
manufacturers submit a new drug application (NDA) to the FDA
prior to marketing the drug in interstate commerce.52
It took yet another disaster to bring about more stringent
changes in the FDA's regulation of drugs. In 1961 Thalidomide was
determined to cause deformities in the children of European women
who took- the drug during pregnancy.53 Although U.S. doctors did
not prescribe Thalidomide because it never received FDA approval,
the drug was distributed to over one thousand women as an investi-
gational new drug. 54 This distribution resulted in seventeen cases of
children born with deformities in the United States.55 In response to
this tragedy, Congress passed the Kefauver-Harris Amendments to
the Food, Drug and Cosmetics Act.56
The new amendments required drug manufacturers to submit to
the FDA data from adequate clinical studies proving that "'substan-
tial evidence' exists that a drug is safe and effective for its intended
use." 57 The Act defined the term "substantial evidence" as meaning
evidence consisting of adequate and well-controlled investiga-
tions, including clinical investigations, by experts qualified by
scientific training and experience to evaluate the effectiveness of
the drug involved, on the basis of which it could fairly and
responsibly be concluded by such experts that the drug will have
the effect it purports or is represented to have under the condi-
tions of use prescribed, recommended, or suggested in the label-
39 AM. U. L. REV. 171 (1989).
49. 21 U.S.C. §§ 301-92 (1982).
50. See Myers, supra note 46, at 311. See also, Myron L. Marlin, Treatment INDs: A
Faster Route to Drug Approval, 39 AM. U. L. REV. 171, 176 (1989).
51. See Meyers, supra note 46, at 312 (citing 21 U.S.C. § 321(g)).
52. Id.
53. See id. at 312, n.17. See also Harvey Teff, Drug Approval in England and the
United States, 33 AM. J. COMP. L. 567 (1985).
54. See Myers, supra note 46, at 312, n.17.
55. Id.
56. Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780 (1962) (codified at 21
U.S.C. §§ 321-381 (1982)).
57. Id.
[Vol. 11:3
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ing or proposed labeling thereof.58
Although, this "definition" did not give drug manufacturers guid-
ance, "towards the end of the 1960s, it became apparent that the
pharmaceutical industry had accepted a formula under which the
FDA required rigorous statistical testing procedures. ' 59 The new
amendments also made it possible to hold manufacturers criminally
liable for failing to notify the FDA of new adverse findings.6" Ap-
proval of the drugs could also be suspended, and later withdrawn, if
the FDA found that use of the drug presented an imminent hazard
to the public.6
B. New Drug Development and Approval
Generally, it is not well known that the FDA does not discover
or test new drugs.6" The FDA reviews the data and proposals of drug
manufacturers who test and seek to market drugs within the United
States.13 "Traditionally, the FDA does not become involved in drug
development until the sponsor, usually a pharmaceutical company,
decides that a potentially useful new drug has been studied suffi-
ciently through laboratory and animal tests to justify the risks of
administration to humans."64
The sponsor of the new drug files an Investigational New Drug
(IND)15 application with the FDA to request a license which ex-
58. 76 Stat. 780, 781 (1962).
59. Harvey Teff, Drug Approval in England and the United States, 33 AM. J. COMP L.
567, 574 (1985).
60. Id.
61. 21 U.S.C. § 355(e) (1982).
62. Ellen C. Cooper, M.D., Changes in Normal Drug Approval Process in Response to
the AIDS Crisis, 45 FOOD DRUG Cosm. L.J. 329 (1990).
63. Id.
64. Id.
65. There are currently three forms of FDA licensing included under an IND applica-
tion. They are: 1) the standard IND (discussed more in depth infra text pp. 8-9), 2) the
"compassionate IND" license, and 3) the "treatment IND" license. See Myers, supra note 46,
at 313-18.
The "compassionate IND" license is "a discretionary permit allowing a patient with an
untreatable terminal illness that is unresponsive to any approved therapy to use an unapproved
drug in a particular way." Id. at 315. This license has allowed many doctors to prescribe
unapproved drugs to patients suffering from cancer, epilepsy and Acquired Immune Deficiency
Syndrome (AIDS), but a drawback is that the applicant must demonstrate that the "benefits
in question outweigh the risks .... Robert Craig Waters, Obtaining Experimental Drugs
for Severely Ill Clients: The Dilemma Caused by AIDS, FLA. B. J., May 1989, at 8. Other
drawbacks with compassionate IND's is the requirements of "extensive recordkeeping, the de-
velopment of extensive protocols, and . . .regulations that often may render the therapy in
question too expensive. For instance, manufactures must supply the drug or therapy without
charge." Id.
The third type of licensing program, the "treatment IND," was established in June 1987
and is "based on the premise that there are times when an experimental drug shows such
promise - especially for a life-threatening condition for which there is no other hope - that
it seems unacceptable to withhold it from desperate patients." Frank E. Young, Experimental
Drugs for the Desperately Ill: A Progress Report, FDA CONSUMER, May 1988, at 2. Treat-
ment IND's can be more widely used, by allowing the prescription to a class of patients rather
RU-486
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empts the sponsor from the FDCA's prohibition of the movement of
unapproved drugs throughout the United States. 6 The standard
IND application must include all information gained from labora-
tory and animal studies conducted and must outline a plan of investi-
gation, detailing .the protocols proposed for anticipated clinical
testing. 6
7
Once a sponsor files a standard IND application, the FDA has
thirty days to review the submitted testing results and determine
whether or not it is reasonably safe to allow the proposed clinical
studies to commence.68 After review, "if the sponsor has submitted
sufficient information to demonstrate that the drug appears reasona-
bly safe for initial, limited testing in humans, the clinical trials may
begin."69 After approving the standard IND application, the FDA
retains the authority to stop the clinical testing if the preliminary
results are not satisfactory."0 Complete testing of standard IND's
can take anywhere from two to ten years. 71
When the sponsor of a standard IND judges that sufficient data
exists to demonstrate that the safety and efficacy of that drug exists
for its proposed purpose, a new drug application (NDA) is filed with
the FDA.72 This application contains all the results and analysis rel-
evant to human use from the IND clinical studies.73 If FDA ap-
proval is granted, the sponsor may market the new drug so long as
safety reports are submitted to the FDA on a regular basis.7 4
than individuals, but many restrictions remain on the drugs that qualify for the treatment
IND. See Myers, supra note 46, at 316. Some of the regulatory requirements for the treat-
ment IND include: "(I) there are no satisfactory alternative treatment for the disease, (2) the
drug is under investigation in clinical trials under an FDA-approved IND, and (3) the sponsor
of the clinical trial is actively seeking approval from the FDA for marketing the new drug -
an NDA." Id. n.49 (citing H.R. Rep. No. 1092, 100th Cong., 2d Sess. 28 (1988). In addition,
.scientific evidence must provide a reasonable basis for concluding (I) that the drug may be
effective and (2) that it would not expose the patient to significant risk of additional illness or
injury." Id.
66. See Cooper, supra note 62, at 329-330; see generally 21 C.F.R. § 312 (1991)
(describing the FDA's method of processing investigational new drug applications). In addition
to the IND application, the sponsor of the drug must also include documents which describe
all "studies to be conducted, provide the identities of those sponsoring the tests, include proto-
cols detailing the course of the study, offer chemical, physiological or biological character of
the drug substance, list the previous human experience with the investigational drug, and fur-
nish any other relevant information requested by the FDA." Myron L. Marlin, Treatment
INDs: A Faster Route to Drug Approval, 39 AM. U. L. REV. 171, 179 n.64 (1989) (citing 21
C.F.R. § 312.23 (1989)).
67. See Myers, supra note 46, at 313.
68. See Cooper, supra note 62, at 330 (citing 21 C.F.R. § 312.35(a) (1989)).
69. Id.
70. Id.
71. See Myers, supra note 46, at 313.
72. See Cooper, supra note 62, at 330.
73. Id.
74. Id. (citing 21 C.F.R. § 314.80-81 (1989)).
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C. Effect of the New Experimental Drug Approval Process
The experimental drug approval process had many positive ef-
fects. Primarily, the safety and effectiveness of these new regulations
boosted consumer confidence and security in drugs marketed within
the United States, as well as prevented the "proliferation of medi-
cally dubious products.1 75 However, the positive benefits of the
amended process are often overlooked in the light of the criticisms
the FDA regulations have received in recent times.
While introducing and marketing a new drug, a sponsor must
cope with extremely high costs as well as long delays. 76 The most
significant adverse effect of the new regulations is the "drug lag,"
defined as "the decrease in new drug innovation and marketing that
results from the strict regulatory climate at the FDA. '77 "Beginning
in 1972, several studies indicated that the United States had lost its
lead in marketing new medicines and that breakthrough
drugs-those that show new promise in treating serious or life-
threatening diseases-had come to be available much sooner in other
countries. 78
In 1973 William Wardell published a series of studies compar-
ing drug introductions in Great Britain with those in the United
States between 1962 and 1971 .7  The outcome of these studies
showed that "approximately fifty percent more drugs were intro-
duced in Great Britain between the years 1962 and 1971, than in the
United States." 80
Recognizing the problems associated with the drug lag, the
FDA attempted to reduce delays.81 In cooperation with other drug
regulatory agencies, the FDA focused on the acceptance of foreign
clinical data.82 This process entails communication between drug
regulatory agencies on an international scale. Communication of
drug information is significant "because it relates to the very basis of
the value of pharmacotherapy in health care: the effective use of
drugs depends on the accurate and comprehensive communication
and understanding about them."83
75. See Myers, supra note 46, at 318.
76. See John Patrick Dillman, Note, Prescription Drug Approval and Terminal Dis-
eases: Desperate Times Require Desperate Measures, 44 VAND. L. REV. 925, 935 (1991).
77. Id. at 936.
78. Mary Graham, The Quiet Drug Revolution: Although The Approval of New Pre-
scription Drugs Takes a Frustratingly Long Time, People Who Are Gravely Ill Can Get
Breakthrough Drugs More Quickly, THE ATLANTIC, Jan. 1991, at 34.
79. See Myers, supra note 46, at 321.
80. Id.
81. See John J. Gorski, Comment, An FDA-EEC Perspective on the International Ac-
ceptance of Foreign Clinical Data, 21 CAL. W. INT'L L.J. 329, 331 (1991).
82. Id.
83. Id. (quoting Hoff, The Role of the Innovation-Based Pharmaceutical Industry in
International Drug Information Communication, 17 DRUG INFO. J. 271 (1983)).
RU-486
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The acceptance of foreign clinical data dates back to 1962 when
the FDA advised the pharmaceutical industry that foreign clinical
data meeting the standards of adequate and well-controlled studies
was acceptable, but could only be used as supplemental information
for proof of a drug's safety and efficacy. 84
"It was not until 1975 that the FDA accepted foreign clinical
studies as primary evidence of a drug's safety and efficacy. But even
at this time, before the FDA would accept the foreign clinical data,
the drug in question must have been for a major health gain, an
uncommon disease, or must have had a strikingly favorable benefit/
risk ratio."85 The FDA currently recognizes two categories concern-
ing the acceptability of foreign clinical data: 1) foreign clinical stud-
ies not conducted under an investigational new drug application
(IND) and 2) marketing approval based solely on foreign clinical
data.8"
84. Id. at 333 (citing Bilstad, Foreign Clinical Data: FDA Perspective, Paper presented
to the Fifth International Meeting of Pharmaceutical Physicians, Munich, Federal Republic of
Germany (Oct. 1984); see also Lisook & Sloboda, Food and Drug Administration Audit of
Foreign Clinical Trials, 23 PSYCHOPHARMACOLOGY BULL. 193 (1987) (citing Weintraub, For-
eign Data: 1986 Status, Paper presented to the 10th Annual Meeting of the Associates of
Clinical Pharmacology, San Francisco, Cal. (Apr. 1986)).
85. Id. (citing Lisook, FDA Investigation of Clinical Studies: Policy and Procedure,
Paper presented at the Third Annual European Symposium, Good Clinical Practice in Europe,
Copenhagen Denmark at 14 (Mar. 3, 1989)).
86. See Gorski, supra note 81, at 334. John Gorski has summarized the recognized cate-
gories as follows:
I. Foreign Clinical Studies Not Conducted Under an IND.
In general, FDA accepts foreign clinical studies not conducted under an IND if
the studies are "well designed, well conducted, performed by qualified investiga-
tors, and conducted in accordance with ethical principles acceptable to the world
community." Studies meeting these criteria may be used to support clinical in-
vestigations and/or marketing approval in the United States. A sponsor who
wishes to rely on foreign clinical studies to support an IND or to support a new
drug application ("NDA") must submit the following information to the FDA:
(1) A description of the investigator's qualifications;
(2) A description of the research facilities;
(3) A detailed summary of the protocol and results of the study, and
should FDA request, case records maintained by the investigator or addi-
tional background data such as hospital or other institutional records;
(4) A description of the drug substance and drug product used in the
study, including a description of components, formulation, specifications
and bioavailability of the specific drug product used in the clinical study,
if available; and
(5) If the study is intended to support the effectiveness of a drug product,
information showing that the study is adequate and well controlled ....
2. Marketing Approval Based Solely on Foreign Clinical Data
The FDA has also promulgated standards under which foreign data can be used
as the sole basis for marketing approval. A new drug based solely on foreign
clinical data may be approved if:
(1) The foreign clinical data are applicable to U.S. population and U.S.
medical practice;
(2) The studies have been performed by clinical investigators of recog-
nized competence; and
(3) The data may be considered valid without the need for an on-site
inspection by FDA or, if FDA considers such an inspection to be neces-
sary, FDA is able to validate the data through an on-site inspection or
Spring 1993]
IV. Drug Approval in Great Britain
A. History and Development
Although both Great Britain and the United States imposed
similarly high standards of medical practice and training and had
research-intensive drug industries, the two countries' regulatory sys-
tems differed significantly between 1962 and 1971 .87
As in the United States, premarket safety reviews of new drugs
did not begin in Great Britain until the Thalidomide tragedy of
1961.88 In 1963, the Committee on Safety of Drugs (CSD), a central
regulatory agency, was created to review toxicity data on new drugs,
results of clinical trials, and postmarket adverse reactions. 89 How-
ever, the premarket review system was voluntary rather than
mandatory.
In an effort to encourage drug manufacturers to utilize the
premarket review system, "the Association of the British Pharma-
ceutical Industry and the Proprietary Association of Great Britain
both agreed that their members would not undertake or market new
medicines contrary to the advice of the CSD."90 These efforts forced
all of the major drug manufacturers to comply with the approval
system because the majority of their domestic trade was with the
National Health Service and doctors.91 While most of the large drug
manufacturers complied with the voluntary premarket review regula-
tions, a number of smaller and less reputable drug manufacturers
refused. This action exemplifies just one circumstance which led to
the enactment of more comprehensive, mandatory provisions for reg-
ulating drugs.92
B. The Medicines Act
In 1971, the Medicines Act of 1968 (Medicines Act) went into
effect and now represents the primary mechanism for prescription
drug regulation in Great Britain.9" Similar to the U.S. Food and
other appropriate means.
If an application fails to meet any of these criteria, it will not be approved on the
foreign clinical data alone . . . .The three criteria listed immediately above are
only relevant if a foreign clinical trial is pivotal for FDA approval (for example,
one of only two clinical trials showing effectiveness). If U.S. data exists which is
convincing per se, and foreign trials confirm the U.S. data, then FDA is not
overly concerned about the foreign data ....
Id. at 334-36.
87. See Henry G. Grabowski & John M. Vernon, The Regulation of Pharmaceuticals:
Balancing the Benefits and Risks 1 (1983) at 38.
88. Id.
89. Id.
90. See Teff, supra note 59, at 575.
91. Id.
92. Id.
93. See Dillman, supra note 76, at 932.
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Drug Administration, one of the Medicines Act's primary purposes
is to "lessen the consumer's vulnerability in the face of dubious mar-
keting techniques. To fulfill this purpose, the Medicines Act im-
posed safety and efficacy requirements, introduced restrictions on the
advertising and promotion of drugs and also introduced provisions to
improve quality control and establish. a system for the licensing and
inspection of manufacturing premises. 95 "The Medicines Act estab-
lished compulsory licensing of drugs through a licensing authority
composed of British health ministers, including the Secretary of
State for Social Services, the Secretaries of State for Wales and
Scotland, and the Department of Health and Social Services for
Northern Ireland."96 Clinical Trial Certificates (CTC's), which al-
low drugs to be administered to human beings, and Product Licenses
(PL's), which allow drug marketing, are issued by the Medicines Di-
vision of the Department of Health and Social Services. 91,
In making drug approval decisions, the Medicines Division of
Health and Social Services is advised by the Committee on the
Safety of Medicines (CSM) and the Committee on the Review of
Medicines (CRM).98 The CSM is the organization responsible for
the safety, quality and effectiveness of all new drug compounds; 99 the
CRM is the organization responsible for drugs in use as of 1975.100
Postmarketing surveillance of prescription drugs is done through
the "yellow card" system.10' The "yellow card" system works
through the cooperation of doctors returning postage-paid postcards
to the CSM when adverse reactions to drugs are reported.10 2
In 1985 tests began on RU-486 in United Kingdom.010 In July
of 1991 the drug was approved for use in Britain,104 primarily be-
cause the British drug approval system is less political than others.
105
V. Differences in Drug Approval; United States v. Great Britain
Although similar, drug approval in the United States has sev-
eral distinctions from Great Britain's process. Congressional regula-
94. See Teff, supra note 59, at 575.
95. Id.
96. See Dillman, supra note 76, at 932 (citing D. Green, Medicines in the Market
Place 34 (1987)).
97. Id.
98. Id.
99. Id.
100. Id.
101. See Dillman, supra note 76, at 932.
102. Id.
103. See Tests Have Begun in the U.K. on the Abortion Drug RU 486, Which is Manu-
factured By Roussel, a Subsidiary of Hoechst, GUARDIAN, June 20, 1985, at 4.
104. See 'Abortion Pill' Approved for Use, Facts on File World News Dig., July Ii,
1991, available in LEXIS, Nexis Library, Facts File.
105. See infra notes 107 and 116-17.
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tion of drug approval is more formal than the English system. 10
"Yet the British approval process has been characterized as scientific
rather than political in comparison with that of the United
States. '10 7 The main difference between the two systems is the regu-
latory philosophy of each.108
The FDA's main concern is to test drugs for adverse effects
prior to the drugs being marketed to the general public.10 9 The FDA
begins reviewing drugs very early and gives less emphasis to
postmarketing review.110 Through extensive testing, "the FDA at-
tempts to discover information relating to adverse drug reactions, ef-
fectiveness, and long-term toxicity in premarketing screening." '
In contrast, Great Britain maintains the premise that no drug is
one hundred percent safe, and that no matter how long a drug is
tested, there will always be a chance that adverse side effects may
occur. 1 Great Britain, therefore, stresses postmarketing monitoring
for these possible adverse reactions. " "Although short-term testing
may uncover most negative side effects, only long-term experience
with a large, widely varied population will reveal the rare, and possi-
bly more serious, reactions:"'1 4 As a result, drugs are approved in
Great Britain on an average of two years sooner than in the United
States. 1 5
Another major difference between the two systems is Great
Britain's use of apolitical committees in the drug approval process.1
These committees are independent from both government and drug
industry influence, allowing scientific evaluation of new drugs with-
out undue influence from governmental bureaucracy or industrial
pressure." 7
106. See Teff, supra note 59, at 579.
107. Rosemary Pierce Wall, Note, International Trends in New Drug Approval Regula-
tion: The Impact on Pharmaceutical Innovation, 10 RUTGERS COMPUTER AND TECH. L.J. 317,
324 (1984) (citing a private interview with an executive in a leading multinational, U.S.-based
pharmaceutical corporation).
108. See Teff, supra note 59, at 579.
109. Id.
110. Id.
11. Dillman, supra note 76, at 933 (citing Harvey Teff, International Trends in New
Drug Approval Regulation: The Impact on Pharmaceutical Innovation 10 RUTGERS COM-
PUTER & TECH. L.J. 317, 325 (1984)).
112. See Teff, supra note 59, at 579.
113. Id.
114. Dillman, supra note 76, at 933 (citing Harvey Teff, International Trends in New
Drug Approval Regulation: The Impact on Pharmaceutical Innovation 10 RUTGERS COM-
PUTER & TECH. LJ. 317, 325 (1984)).
115. See Wall, supra note 107, at 325.
116. See Dillman, supra note 76, at 933-34.
117. Id.
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VI. Other Countries
A. Sweden
In October of 1992 the Swedish authorities approved the use of
RU-486, allowing the drug to be prescribed only by doctors. 118 The
Swedish approach to drug regulation shows a cautiousness toward
the approval of new drugs that rivals the United States.119 Sweden,
like Great Britain, uses a nationalized health care system to conduct
postmarketing surveillance for adverse effects associated with new
drugs. 2 ' However, unlike Great Britain, "the philosophy of Swedish
nationalized health care permeates decision making by the National
Board of Health and Welfare (NBHW)."' 21
Until 1980, Sweden traditionally allowed human testing of new
drugs with only mandating a notice requirement.1 22 In 1980, Swed-
ish authorities adopted a proposal which restricted the approval cri-
teria, imposing requirements similar to those of the United States
and Great Britain.1 23
B. France
The Office of Pharmaceutical Control, which reports to the
Minister of Public Health, is the regulating agency of France. 24
France historically has not regulated consumer protection as compre-
hensively as the United States, but, over the last fifteen years, the
regulation has grown more stringent.1 25
In France, to market products that may put the life or health of
consumers at risk, a manufacturer must obtain a "visa" or authori-
zation from the Office of Pharmaceutical Control.1 2 Authorization
is granted for medical drugs only when drug companies establish
that the drug is manufactured under high standards and that it is
harmless to consumers.1 2 7 This marketing authorization is only tem-
porary and must be renewed periodically.1 28
In 1982, the French government "established the National
Commission on Drug Monitoring to facilitate the gathering of data
on adverse reactions to drugs subject to authorization. Its primary
118. Roussel-Uclaf - Abortion Pill Approved In Sweden, CHEMICALS BUSINESS NEWS
BASE, Oct. 2, 1992, at 4.
119. See Wall, supra note 107, at 327.
120. Id.
121. Id.
122. Id.
123. Id.
124. See Anne E. Wells, Regulating Experimental AIDS Drugs: 4 Comparison of the
United States and France, 13 Loy. L.A. INT'L & COMP. L.J. 393, 402 (1990).
125. Id. at 401.
126. Id. at 402.
127. Id.
128. Id.
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functions include 'compil[ing] and evaluat[ing] information on the
unexpected or toxic effects of medicaments.' "129
The French authorization system requires a manufacturer of a
new drug to conduct clinical investigations in France, on French citi-
zens before the drug will be granted marketing approval. 130 The
French government controls and pays for drug costs as part of its
national social security system. 1' "Because it ultimately subsidizes
the cost of drugs to the French consumer, the French government
has taken steps to encourage the pharmaceutical industry to estab-
lish research operations and manufacturing in France, rather than to
continue to import drugs from abroad." 132
On September 23, 1988, France's Health Minister, Claude
Evin, announced that RU-486 was granted marketing approval.133
Professor Jean-Michel Alexandre, President of the Medical Sales
Commission, stated in a news conference that experiments conducted
with RU-486 showed a more than ninety-five percent success rate in
women administered the drug. 34
For more than one month, French women who wished to obtain
the drug to terminate a pregnancy could do so from doctors in spe-
cialized family planning centers. 35 However, on October 26, 1988,
Roussel Uclaf withdrew RU-486 from the French drug market after
receiving what it called "an emotional response from parts of French
and foreign public opinion.1"131 Pierre Joly, Vice-Chairman of Rous-
sel Uclaf, stated that the company had received threats of boycotts
of Roussel Uclaf drugs as well as anonymous threats of violence
aimed at the wives and children of the company's executives. 37 Al-
though these threats were anonymous, Health Minister Claude Evin
suspected that it was the work of the same militant Catholics and
anti-abortionists who in the early 1970's campaigned against the
abortion law.' 38
Two days later, Mr. Evin told French television that "[f]rom
the moment government approval for the drug was granted . . . RU
486 became the the [sic] moral property of women, not the property
129. Wells, supra note 124, at 402 (quoting Journal Officiel de la Republique Fran-
caise, Edition des Lois et Decres Recueil Dalloz, August 4, 1982, No. 179, at 2498).
130. Id. at 403.
131.. Id.
132. Id. at 404 (citing Kruezer, International Drug Registration, 43 FOOD DRUG COSM.
L.J. 559, 560 (1988)).
133. France Becomes First Western Nation to Approve Abortion Pill, supra note 3 1, at
4.
134. Id.
135. Id.
136. Philippe Naughton, French Government Orders Company to go Ahead With Abor-
tion Pill, REUTERS, Oct. 28, 1988, available in LEXIS, Nexis Library, Reuter File.
137. Id.
138. Id.
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of the drug company."139 Mr. Evin ordered Roussel Uclaf to ignore
the anonymous threats and to continue marketing the drug."1 0
VII. Why RU-486 is Unavailable in the United States
There are numerous reasons why RU-486 is not available in the
United States. These include the FDA ban on the importation of the
drug for personal use, " " President Bush's hostile attitude towards
abortion, boycott threats from anti-abortion organizations, Roussel
Uclaf's unwillingness to supply the drug to the United States as well
as the exorbitant costs involved in introducing and marketing a new
drug.
A. President Bush and Politics in the FDA
Over the past four years, the Bush Administration had a hostile
attitude towards abortion. This position was evident by President
Bush's "gag-rule" which prohibited abortion counselling at federally
financed family planning clinics."'
Because of the Bush Administration's objections to abortion, the
FDA indicated that it would not approve clinical trials of RU-486.1'
With this attitude from the FDA, pharmaceutical companies were
reluctant to begin the long, expensive FDA approval process.
B. Roussel Uclafis Reluctance
With the resistance Roussel Uclaf experienced soon after mar-
keting RU-486 in France, the company stated that it would not sell
RU-486 in countries where the social climate remains hostile toward
abortion. 1" ' Since anti-abortion groups in the United States
threatened to boycott all products of any drug company attempting
to market RU-486,' 5 no pharmaceutical companies have ventured to
market the drug." Even if Roussel Uclaf were willing to market the
drug in the United States, the company would have a difficult time
139. Id.
140. Id.
141. See infra text pp. 22-23.
142. On the day of the 1992 Presidential election, a federal appellate court invalidated
the "gag-rule." Since President Clinton's Administration is not expected to appeal this decision
to the United States Supreme Court, the regulation should become moot. See Sara Engram,
Clinton Era Means Reproductive Freedom For Women, TORONTO STAR, Nov. 9, 1992, at DI.
143. See Elaine Herscher, SF Doctors Propose Testing Controversial Abortion Pill, SF.
CHRON., Apr. 3, 1990, at Al.
144. See Tamar Lewin, After Furor, Americans Are No Closer to Having Abortion
Pill, N.Y. TIMES, July 24, 1992, at D16.
145. See Herman, supra note 20, at Z13.
146. The Upjohn company has closed its reproductive research unit, removed one abor-
tion drug from the market and decided not to market another. This is partially do to a nation-
wide boycott from 1983 to 1985 of Upjohn products, including Nuprin, Motrin, and Unicap
vitamins. See Lees, supra note 34, at 1122.
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finding an American company willing to be a licensed partner for
distribution.4 7 Even Roussel Uclars United States subsidiary, lo-
cated in Somerville, New Jersey, declined to market the drug. 148
Some experts on the politics of abortion have stated that "Roussel
Uclaf will not try to sell RU486 in the United States until there is a
President who favors abortion rights."' 9 Until Roussel Uclaf seeks
to introduce the drug in the United States, the FDA is not required
to review it.
C. Economic Difficulties
A drug manufacturer wishing to market RU-486 in the United
States would have a market of approximately $200-250 million per
year available. 5 ' However, the possibility of boycotts prevents larger
drug manufacturers from marketing RU-486. The market available
for RU-486 is minuscule when compared with the markets for an-
tibiotics, anti-hypertension and anti-arthritic drugs which are worth
billions of dollars. 51
A smaller drug company, with fewer products, would not be as
severely affected by a boycott.152 However, because the preparation
of new drugs for marketing takes many years and can cost a drug
manufacturer several million dollars in clinical tests and legal
fees, ' 5 3 smaller drug companies do not have the economic and legal
resources necessary to sustain the drug's manufacture. Readying
RU-486 for FDA approval could cost anywhere from $50-100 mil-
lion.154 Assuming the drug were to be approved by the FDA, another
$125-200 million is needed to market and distribute the drug. 1' Fi-
nally, given the legal climate in awarding damages, 56 a company
marketing RU-486 could be subjected to exorbitant court
judgements.157
147. See Herman, supra note 20, at Z12.
148. Id.
149. See Lewin, supra note 144, at D16.
150. See Arnold Abrams, Politics, Profits And a New Pill; U.S. Women May Never
Have Access to RU 486 For Abortions, NEWSDAY, Dec. 13, 1988, (Discovery Section), at 6.
151. Id.
152. See Chapman, supra note 21, at Z13.
153. Id.
154. Id.
155. Id.
156. In 1985, a jury awarded a Georgia woman $4.7 million dollars in damages for a
claim that a spermicide made by Ortho Pharmaceuticals was the cause of her child's birth
defects. See id.
157. See Chapman, supra note 21, at Z13.
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VIII. Recent History
A. The Personal Use Exception
The FDA possesses the authority to prohibit the importation of
drugs that are not approved pursuant to the laborious regulation pro-
cess. The FDA also possesses the authority to permit the importation
of drugs not yet approved.1 58
On July 20, 1988, the FDA initiated a pilot program that, if
successful, would revise the Regulatory Procedure Manual (RPM)
Chapter 9-71 to allow persons suffering from cancer and AIDS to
import small doses of unapproved drugs for their own personal
use.' 59 On September 26, 1988, the FDA issued Import Alert 66-
813, stating that "the July 20, 1988, pilot program on mail importa-
tions did not apply to RU486, presumably because the drug has
nothing to do with the treatment of AIDS or cancer." 60
On February 1, 1989, the FDA deemed the mail importation
pilot program a success and formally revised the agency's RPM. The
revision not only expanded the pilot program from mail order im-
ports to include imports in personal luggage, but it also included
drugs for "all life-threatening or serious conditions whether or not
AIDS-related or the result of cancer, as well as less than serious
medical conditions where the product 'is not known to represent a
significant health risk.' "161 This revision became known as the "per-
sonal use exception.' 6 2
158. See 21 U.S.C. § 381(a)(3) (1982); see also Heckler v. Chaney, 470 U.S. 821
(1985).
159. See Benten v. Kessler, 799 F. Supp. 281, 285 (E.D.N.Y. 1992).
160. Id.
161. Id. at *11 (quoting the Food and Drug Administration Regulatory Procedure
Manual).
162. Id. The RPM reads in pertinent part:
In deciding whether to exercise discretion to allow personal shipments of drugs
or devices, FDA personnel should consider a more permissive policy in the fol-
lowing situations:
[W]hen the intended use is appropriately identified, such use is not for treatment
of a serious condition and the product is not known to represent a significant
health risk; or when
(1) the intended use is unapproved and for a serious condition for which
effective treatment may not be available domestically either through com-
mercial or clinical means;
(2) there is no known commercialization or promotion to persons residing
in the United States by those involved in the distribution of the product
at issue;
(3) the product is considered not to represent an unreasonable risk; and
(4) the individual seeking to import the product affirms in writing that it
is for the patient's own personal use (generally not more than three
months supply) and provides the name and address of the doctor .licensed
in the U.S. responsible for his or her treatment with the product or pro-
vides evidence that the product is for the continuation of a treatment be-
gun in a foreign country.
Id. at *11-12 (quoting the FDA Regulatory Procedure Manual) (emphasis added).
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B. Import Alert 66-47
The "personal use exception," in effect, nullified Import Alert
66-813 by allowing the importation of drugs whether or not the use
was AIDS or cancer related. Shortly thereafter, the FDA was criti-
cized for failing to exclude RU-486 from the "personal use excep-
tion." Just a few months after the "personal use exception" went
into effect, the Commissioner of the FDA began receiving correspon-
dence from several United States legislators voicing their disapproval
of allowing the importation of RU-486. e3
On June 6, 1989, the FDA issued Import Alert 66-47, which
concluded that the importation of unapproved abortifacients was in-
appropriate for release under the personal importation policy.'6 4 The
Import Alert states that RU-486 could pose a risk to the safety of
the user and should therefore be subject to automatic detention by
customs officials. 65
The FDA Import Alert represents a mechanism for stopping
improperly labeled or otherwise nonconforming drugs from importa-
tion into the United States.' By issuing an import alert, the FDA
"can hold a product for review, then presumptively deny entry.' 6 7
C. Ms. Leona Benten
Ms. Benten, a politically active feminist, volunteered to be the
test plaintiff to challenge the FDA's ban on RU-486. 6 8 Ms. Benten
contacted friends at the Woman's Clinic in Oakland, CA, regarding
an abortion, who put her in touch with the Abortion Rights Mobili-
163. See Benten v. Kessler, 799 F. Supp. at 285-86. Judge Sifton states in his opinion
that on May 5, 1989, Congressmen Robert K. Dornan, Henry Hyde, and John LaFalce sent a
letter to the then Commissioner of the FDA expressing their concern that RU-486 was not
listed as one of 40 drugs specifically excluded from importation in a 1988 article in American
Health, entitled "Mail Order Drtgs From Abroad." Pertinent portions of that letter state:
We are aware of the September 26, 1988 memo signed by Burton I. Love [Alert
66-813] but we have seen no official statement from you confirming the ban on
RU 486.
The U.S. government should not be involved in abetting abortion. This in-
cludes regulations that would allow the use of abortifacients such as RU
486. . . .How could the FDA possibly allow it to be purchased through mail
order?!
Id. at 286.
164. See id. at 286.
165. Id. Judge Sifton held in Benten, that Import Alert 66-47 was issued "not from any
bonafide concern for safety of users of the drug, but on political considerations having no place
in FDA decisions on health and safety." Id. The Judge came to this conclusion after observing
the differing rationales offered by the FDA, the influential correspondence directed to the then
Commissioner, and the limited time taken by the FDA to consider the issue. Id. at n.3.
166. See IFSCC Congress Hears Regulatory Progress Report; International Federation
of Societies of Cosmetic Chemists, DRUG AND COSMETIC INDUSTRY, November 1990,-Vol.
147, No. 5, at 38.
167. Id.
168. See Tamar Lewin, Woman at Center of Debate: Model of an Ardent Feminist,
N.Y. TIMES, July 16, 1992, at AI8.
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zation.'8 9 For months, the Abortion Rights Mobilization had been
trying to obtain RU-486 and a young woman willing and suitable to
test the FDA's ban.170
For many years, Ms. Benten actively voiced her opinion on such
issues as abortion rights, prisoner's rights, lesbian rights, AIDS edu-
cation and women in nontraditional jobs.' 7 Ms. Benten volunteered
to import RU-486 from England to force a court challenge "so that
women [could] benefit from [the] drug.' 72
On July 1, 1992, customs officials, after receiving notification by
the Abortion Rights Mobilization of their plan to import the drug,
seized twelve RU-486 pills from Ms. Benten at John F. Kennedy
International Airport. 173
D. Benten v. Kessler174
Shortly after the RU-486 pills were seized, Ms. Benten initiated
an action against Mr. David Kessler, the Commissioner of the FDA,
challenging the FDA's ban of RU-486. In her complaint, Ms.
Benten alleged that the FDA illegally promulgated the ban on im-
portation of RU-486 and sought to secure the return of the drug as
well as enjoin the enforcement of the ban. 1 5
Judge Charles P. Sifton, sitting for the Federal Eastern District
Court of New York, held that the United States Customs Officials
and the FDA proceeded illegally when they confiscated the pills and
ordered the release of the drug to Ms. Benten.17 1 Judge Sifton also
denied Ms. Benten's broader request for a preliminary injunction
against enforcement of the ban. 77
In concluding that the FDA proceeded illegally, Judge Sifton
stated that "[t]his was a lawsuit waiting to happen. The record...
reveals a history of political and bureaucratic timidity mixed with
well-intentioned blundering in dealing with two of the most charged
and significant issues of our time: AIDS and abortion."1 7 8 Adoption
of the "personal use exception" by the FDA was without the re-
quired notice of the rulemaking and opportunity for comments by
169. Id.
170. See Philip J. Hilts, Judge Overturns Federal Seizure of Abortion Pill, N.Y. TIMES,
July 15, 1992, at Al.
171. See Lewin, supra note 168, at I.
172. See Hilts, supra note 5, at 12.
173. id.
174. Benten v. Kessler, 799 F. Supp. 281 (E.D.N.Y. 1992).
175. See generally, id.
176. Id. at 283.
177. See id. Judge Sifton held that whether or not the drug should be available in the
United States was not before the Court and should be heard by the agency assigned the task of
reviewing such matters. Id.
178. Benten v. Kessler, 799 F. Supp. at 282.
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the public.'79 Also, when the FDA issued Import Alert 66-47, no
notice and comment procedures preceded or followed the issuance.180
Ms. Benten took "advantage of this sink of illegality to relieve her
own understandable anxieties over employing surgical procedures to
end her unwanted pregnancy. "181
. Ms. Benten's victory was short lived. Before the pills could be
returned to Ms. Benten, the United States Court of Appeals for the
Second Circuit in Manhattan stayed Judge Sifton's order." 2 Ms.
Benten immediately filed an emergency request with the United
States Supreme Court to uphold Judge Sifton's order and overrule
the Appellate Court's stay.' 83 Ms. Benten filed for emergency review
because she had only a few days left to terminate her pregnancy
through the use of the pills. Justice Clarence Thomas took the ap-
peal and asked the Justice Department to submit its argument so he
could make an expedited decision.1 4
On July 18, 1992, the last day Ms. Benten could be assured that
the pills would terminate her pregnancy, the United States Supreme
Court, in a seven to two decision, refused to order the Federal Gov-
ernment to return the RU-486 pills. 18 5 The unofficial Supreme Court
decision stated that "the petitioners failed to demonstrate substantial
likelihood of success on the merits of the claim that an administra-
tive document instructing enforcement officials to seize the drug was
promulgated without notice-and-comment procedures assertedly re-
quired under both the Administrative Procedure Act and FDA
regulations.' 86
Further supporting the claim that the FDA allowed political in-
fluence to color their decision to ban RU-486 for use as an abortifa-
cient, the FDA recently allowed Mr. John David Grow to import
small amounts of the drug for his personal use.187 Mr. Grow suffers
from an aggressive recurrent meningioma (a tumor of the lining of
the brain) and was granted approval by the FDA to use the drug as
an experimental treatment.188
179. See id. at 285.
180. Id. at 286.
181. Id. at 283.
182. See Philip J. Hilts, Justices Uphold Federal Seizure of Abortion Pill, N.Y.TiMES,
July 18, 1992, at LI.
183. See Philip J. Hilts, Thomas Expedites Suit on Abortion Pill, N.Y. TIMES, July 16,
1992, at A18.
184. See id.
185. See Hilts, supra note 182, at LI.
186. Benten v. Kessler, No. A-40, 112 S. Ct. 2929; 1992 U.S. LEXIS 4756; 61
U.S.L.W. 3081; 92 Daily Journal DAR 10280 (July, 17, 1992).
187. See Man Gets Abortion Pill to Treat Cancer, L.A. TIMES, Aug. 8, 1992, at A12.
188. Id.
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IX. Conclusion
To date, RU-486 may not be imported into the United States to
terminate an unwanted pregnancy. As seen in the past, prohibition is
not effective as a deterrent. If American women are determined to
obtain RU-486, the FDA's ban will not stop their pursuit.
This ban may lead to the creation of a dangerous black market
for the drug. The drug may be smuggled into this country, as are
other drugs such as cocaine and heroine; some may try to reproduce
the drug in underground laboratories which could lead to a similar,
but dangerous chemical compound; and yet others may intentionally
sell drugs purposefully misrepresented as RU-486 to profit from
those women who are desperate enough to buy the drug on an illegal
market.
Women must make the difficult decision whether or not to ter-
minate an unwanted pregnancy. A woman must consider, as part of
this decision, the dangers associated with surgical abortions as well
as possible political pressures from anti-abortion groups.
RU-486 simplifies this difficult decision. It offers women a safe
alternative to surgical abortions and, at the same time, offer more
privacy through administering the drug in doctors' offices or even the
woman's home.
The FDA must put aside the politics associated with the abor-
tion debate and focus on RU-486's safety. If the benefits offered by
this drug outweigh the risks, it should be marketed within the
United States.
The future of RU-486 is uncertain, but there is hope. On No-
vember 3, 1992, former Governor of Arkansas, Mr. Bill Clinton was
elected President of the United States, defeating the incumbent,
George Bush. President Clinton believes a woman should have a
choice in deciding whether or not to have an abortion. On his cam-
paign trail, President Clinton called on the FDA to stop playing
politics with RU-486.18 9 Dr. Sharon Camp of the Washington-based
Population Crisis Centre predicts that with Mr. Clinton in the White
House, RU-486 will be available in the United States within the
next five years190*
Mark A. Hernandez
189. See Michael K. Frisby, Clinton's Currency Rises with the Polls; Democrats Jump
on Bandwagon as Public Responds; Campaign '92, B. GLOBE, July 29, 1992, at 10.
190. See Engram, supra note 142, at 1.
* Since taking office, President Clinton has changed the political atmosphere pertaining
to RU-486 and abortion in general. In January, President Clinton directed the Secretary of
Health and Human Services to instruct the FDA to determine whether the current ban on
RU-486 is justified, and to rescind the ban if there is no basis for it.
In March Roussel-Uclaf announced that President Clinton had shown an interest in mak-
ing RU-486 available to American women, and it would therefore supply the drug for clinical
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testing in the United States. In April, Roussel-Uclaf agreed to license RU-486 to the Popula-
tion Council, a not-for-profit research organization located in New York. The Population
Council plans to sponsor clinical trials involving approximately 2,000 women in the United
States and would also sponsor an application to the FDA for approval to market the drug. The
Population Council plans to raise four million dollars for the sponsorships and hopes to have
the drug approved for marketing in the United States within two years.
Recently, England's Dept of Health authorized the Marie Stopes Health Clinic to offer
RU-486 to American women who travel to England & pay $600 to terminate their pregnancy.
Planned Parenthood believes the decision signals a warming trend toward RU-486 generally."
British Offering Abortion Drug to U.S. Women, N.Y. TIMES, Feb. 18, 1994, at Al.

